Dose limiting toxicity trang 1 tải miễn phí từ tailieunhanh

"Dose limiting toxicity" trang 1 - tải miễn phí từ tailieunhanh

Dynapenia could predict chemotherapyinduced dose-limiting neurotoxicity in digestive cancer patients

Dynapenia could predict chemotherapyinduced dose-limiting neurotoxicity in digestive cancer patients

9 72 1

Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy

Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy

9 1 1

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

8 46 1

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

10 64 1

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

13 51 0

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

10 45 1

A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma

A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma

9 52 1

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

8 66 1